A.I.D.S. Expected In Heterosexuals (Press, 18 September 1984)

In a significant statement regarding the spread of the virus believed to cause Acquired Immune Deficiency Syndrome (AIDS), Dr Robert Gallo from the National Cancer Institute indicated that the virus, known as H.T.L.V. 3, has dispersed more widely than initially anticipated. He highlighted that it is likely to be found beyond the previously identified high-risk groups, which predominantly include homosexual men, haemophiliacs, Haitians, and intravenous drug users. Dr Gallo reaffirmed, however, that he does not consider AIDS to be on the verge of becoming an epidemic. During a symposium on cancer held in Boston, Dr Gallo revealed findings suggesting that the virus is now detectable in a variety of locations, including the United States, Australia, Finland, Britain, Italy, Germany, and certain African nations. He noted, “What we have is evidence in the last six months that the virus has spread much more than we had originally believed possible.” He added that a small fraction of individuals showing signs of infection with the H.T.L.V. 3 virus are expected to develop AIDS, as explained by Dr Jerome Groopman from Boston’s New England Deaconess Hospital. Both medical professionals cautioned against fearing an oncoming epidemic among the heterosexual population. Dr Gallo speculated that the virus, or a family of related viruses, may have originated in Africa, potentially transmitted to the Americas through the slave trade. According to statistics reported by the Centres for Disease Control by September 3, 1984, there had been 5,896 reported cases of AIDS in the United States since 1979, with 2,688 deaths, representing 46 percent of diagnosed cases. In related developments, scientists working with the Chiron Corporation in San Francisco reported progress in their research aimed at creating an experimental vaccine against AIDS. They indicated that with successful cloning of the virus's genes, they could be ready to begin testing a vaccine designed to protect healthy individuals from contracting the disease within six to eight months. Following the vaccine development, animal and human trials would then take place, a process that could extend over several months or years before any potential approval for widespread use. Overall, these advancements underline the urgency and complexity of addressing the AIDS crisis, while underscoring the varied transmission patterns of the virus and the ongoing research efforts aimed at finding viable prevention techniques.

The text on this page is created, in the most part, using Generative AI and so may contain errors or omissions. It is supplied to you without guarantee or warranty of correctness. If you find an error or would like to make a content suggestion please get in contact

The text on this page is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 New Zealand